Saturday, 21 September 2013

Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage

As a company with a 90 year history dedicated to diabetes care, research, and education, Novo Nordisk has always put patients first. We would like to respond and set out our position on the recent articles and related commentary on incretins and pancreatic damage (British Medical Journal)

No comments:

Post a Comment